Armenia grants Agenus first marketing approvals for Botvymo-Evamplix combo in MSS metastatic colorectal cancer

• Armenia granted the first marketing authorizations worldwide for Agenus’ Botvymo (botensilimab) and Evamplix (balstilimab) as a combination regimen.
• Clearance covers previously treated adults with MSS metastatic colorectal cancer without active liver metastases.
• Authorizations took effect Oct. 2, 2026; approvals are conditional for one year, renewable with annual clinical updates.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610080730BIZWIRE_USPR_____20261008_BW022628) on October 08, 2026, and is solely responsible for the information contained therein.